Sivik Global Healthcare LLC Buys New Position in Qiagen (NYSE:QGEN)

Sivik Global Healthcare LLC purchased a new position in shares of Qiagen (NYSE:QGEN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 55,000 shares of the company’s stock, valued at approximately $2,389,000.

Other institutional investors also recently added to or reduced their stakes in the company. Sector Gamma AS raised its holdings in shares of Qiagen by 89.2% in the fourth quarter. Sector Gamma AS now owns 190,539 shares of the company’s stock valued at $8,275,000 after buying an additional 89,826 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Qiagen by 15.6% in the 4th quarter. Jennison Associates LLC now owns 1,308,304 shares of the company’s stock valued at $56,820,000 after purchasing an additional 176,496 shares during the last quarter. Duality Advisers LP increased its holdings in shares of Qiagen by 183.4% in the fourth quarter. Duality Advisers LP now owns 56,035 shares of the company’s stock valued at $2,434,000 after purchasing an additional 36,261 shares during the period. Signaturefd LLC raised its stake in shares of Qiagen by 54.4% during the fourth quarter. Signaturefd LLC now owns 7,236 shares of the company’s stock worth $314,000 after purchasing an additional 2,550 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in shares of Qiagen by 21.6% during the fourth quarter. Lindbrook Capital LLC now owns 1,335 shares of the company’s stock worth $58,000 after purchasing an additional 237 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on QGEN. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a research note on Thursday, February 8th. Citigroup dropped their price target on shares of Qiagen from $61.86 to $60.00 and set a “buy” rating on the stock in a research note on Thursday, February 8th. Finally, Morgan Stanley raised shares of Qiagen from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $49.48 to $51.00 in a report on Friday, February 16th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Qiagen currently has a consensus rating of “Moderate Buy” and an average target price of $51.69.

Qiagen Price Performance

QGEN stock traded up $0.03 during trading on Tuesday, reaching $42.33. 2,113,233 shares of the company were exchanged, compared to its average volume of 1,220,508. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.62 and a current ratio of 1.99. The stock’s 50 day moving average price is $42.57 and its 200 day moving average price is $42.69. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.70. The company has a market cap of $9.66 billion, a P/E ratio of 27.98, a PEG ratio of 3.51 and a beta of 0.41.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, April 29th. The company reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. Qiagen had a return on equity of 12.99% and a net margin of 17.37%. The business had revenue of $459.00 million for the quarter, compared to analyst estimates of $453.91 million. During the same quarter in the previous year, the company earned $0.53 EPS. The company’s quarterly revenue was down 5.4% on a year-over-year basis. As a group, analysts predict that Qiagen will post 2.09 earnings per share for the current fiscal year.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.